Skip to content
You are now leaving https://www.ionispharma.com to visit

Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

TEGSEDI provides powerful knockdown of TTR protein, delivering significant and sustained benefits in neuropathy and quality of life Hereditary Transthyretin (hATTR) Amyloidosis Infographic AKCEA CONNECT™ Infographic TEGSEDI™ (inotersen) Product Shot Ionis Pharmaceuticals Logo TEGSEDITM(inotersen)